Adam Feuerstein from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 12 days ago STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - 12 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - 24 days ago STAT+: Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - 25 days ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 28 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago STAT+: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago STAT+: Can iTeos and GSK solve TIGIT’s troubles? - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 2 months ago STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 3 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago STAT+: On Andrew Left and the government’s fraud case - 4 months ago STAT+: Sage suffers pipeline setback with failure of drug to treat essential tremor - 4 months ago STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet? - 4 months ago A biotech’s binary bet ends badly - 5 months ago STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more - 6 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 6 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 7 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 7 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 7 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 8 months ago STAT+: Weed for weight loss, and more from Biotech Land - 8 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 8 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 8 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 8 months ago STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH - 8 months ago STAT+: First medicine developed to treat MASH expected to be approved soon - 8 months ago STAT+: Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study - 8 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 8 months ago STAT+: In stunning outcome, Amylyx’s ALS drug fails large clinical trial - 8 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 9 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 9 months ago STAT+: An inside look at PIPEs, the financing trend that has biotech abuzz - 9 months ago STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves - 9 months ago STAT+: Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence - 9 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 9 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study - 9 months ago
2	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - 12 days ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 28 days ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 6 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 7 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 7 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 8 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 8 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 8 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 9 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 9 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 9 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago
5	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 3 months ago
6	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 7 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 8 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 8 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 8 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 9 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 9 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 9 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago